Target intelligence / Profile preview

Globus pallidus internus (GPi)

Target
GPi
Molecular classification
Other (Subcortical brain nucleus; not a molecule, receptor, enzyme, transporter, or classical molecular target)
01

Overview

The **globus pallidus internus** (**GPi**) is the medial segment of the globus pallidus—a subcortical nucleus that forms part of the basal ganglia system in the human brain. It serves as one of two main output nuclei for the basal ganglia network—the other being substantia nigra pars reticulata—and exerts tonic inhibitory control over thalamic nuclei involved in motor planning and execution. The GPi receives major inhibitory input from striatum neurons via GABAergic pathways and integrates additional signals from both external globus pallidus and subthalamic nucleus through direct and indirect pathways. Its primary function is regulation and fine-tuning of voluntary movements by modulating thalamocortical activity; dysfunction can result in various hyperkinetic or hypokinetic movement disorders including Parkinson’s disease and dystonia. The GPi has become an important clinical target for neuromodulatory therapies such as deep brain stimulation aimed at alleviating symptoms refractory to pharmacological treatment[1][6][7].

Other names
Internal globus pallidusMedial globus pallidusGPi
02

Mechanism of action

For therapies targeting this structure (e.g., DBS): - Modulation of abnormal neuronal firing patterns in the GPi to restore balance in basal ganglia-thalamo-cortical circuits.

03

Biological functions

Regulation of voluntary movementInhibitory output within the basal ganglia circuitryModulation of thalamic activity and motor planningIntegration of cortical signals via basal ganglia pathways
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease and dystonia)Movement disorders (e.g., dyskinetic cerebral palsy)
05

Safety considerations

Surgical risks associated with deep brain stimulation procedures (hemorrhage, infection)Potential for cognitive or psychiatric side effects following intervention due to disruption/modulation of basal ganglia circuits
06

Interacting drugs

No direct small-molecule drugs interact with the GPi itself as it is not a receptor or enzyme. However, it is targeted by neurosurgical procedures such as deep brain stimulation.
07

Biomarkers

None specific to patient selection for GPi targeting; selection typically based on clinical diagnosis and neuroimaging findings relevant to movement disorder phenotypes.

Beyond the preview

Go deeper on Globus pallidus internus (GPi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Globus pallidus internus (GPi).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call